News

Odyssey Health, Inc. Announces Successful Completion of Phase I Clinical Trial for Concussion Drug

Las Vegas, Nevada, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a…

2 years ago

MaxCyte Signs Strategic Platform License with Vertex Pharmaceuticals to Advance CRISPR/Cas9-based Gene-editing Program

Vertex Pharmaceuticals will continue to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support gene-edited cell therapy exa-cel, formerly…

2 years ago

RAPT Therapeutics Strengthens Leadership Team with Two New Key Hires

SOUTH SAN FRANCISCO, Calif., Sept. 28, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company…

2 years ago

Rakovina Therapeutics Announces Upcoming Scientific Conference Presentations

Presentations to highlight continued progress toward initiation of human clinical trials with novel DNA-damage response inhibitorsVANCOUVER, British Columbia, Sept. 28,…

2 years ago

Nuvectis Pharma Announces Formation of a Scientific Advisory Board

FORT LEE, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development…

2 years ago

CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX130™ for the Treatment of Cutaneous T-Cell Lymphomas (CTCL)

ZUG, Switzerland and BOSTON, Sept. 28, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating…

2 years ago

Gradalis to Host Key Opinion Leader Webinar on Unmet Medical Needs in Ovarian Cancer and the Company’s Immuno-Oncology Treatment, Vigil®

-Webinar to feature presentations from Rodney Rocconi, M.D. and John Nemunaitis, M.D., on Monday, October 3rd at 1:00 p.m. ET DALLAS,…

2 years ago

Monopar to Present at Roth Inaugural Healthcare Opportunities Conference

WILMETTE, Ill., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing…

2 years ago